anti il 17f neutralization polyclonal antibody  (R&D Systems)

Journal: Arteriosclerosis, Thrombosis, and Vascular Biology

Article Title: Role of Interleukin 17 in Inflammation, Atherosclerosis, and Vascular Function in Apolipoprotein E–Deficient Mice

doi: 10.1161/atvbaha.111.227629

Figure Lengend Snippet: Figure 4. Effect of IL17 on angiotensin II–induced atherosclerosis and examination of IL17F levels. ApoE/ and IL17/ApoE/ mice were infused with angiotensin II for 4 weeks via osmotic minipump. Atherosclerotic lesions in the thoracic aortas were quantified by planimetry (A). Example aortas are shown on the left, and summary data are shown on the right (n7 per group; Pnot significant). Splenic lymphocytes from ApoE/ and IL17/ApoE/ mice fed regular (Reg) or high-fat (HF) diet for 3 months were cultured on anti- CD3 plates, and IL17F released into the media was measured by ELISA (B) (n5 to 7 per group). Data were analyzed using the Stu- dent’s t test. The statistical values in panel B represent a Bonferroni correction for 4 comparisons.

Article Snippet: To examine a potential role of IL17F, IL17A/ApoE / were treated with anti-IL17F neutralization polyclonal antibody (100 g/mouse per injection, catalog no. AF2057, R&D Systems) or its isotype control (goat IgG, 100 g/mouse per injection, catalog no. AB-108-C, R&D Systems) once a week for 3 weeks starting 1 week before carotid ligation.

Techniques: Cell Culture, Enzyme-linked Immunosorbent Assay